Trending Topic

Inflammation of the breast in women. Female breasts with signs of the disease. A low-poly construction of interconnected lines and points. Blue background.
5 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Mohammad Ammad Ud Din, Hania Liaqat, Ayesha Tayyab

The incidence rate of breast cancer (BC) is the highest in Pakistan among all Asian countries.1 In 2018 alone, 2.1 million cases were diagnosed, although the exact number is likely much higher due to poor reporting in rural areas and the lack of a formal national cancer registry.1,2 Over the last decade, multiple non-governmental organizations and large […]

Martin Hutchings, EHA 2018 – ECHELON-1 trial and chemotherapy regimens in Hodgkin’s lymphoma

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 20th 2018

Martin Hutchings from Copenhagen University Hospital discusses the ECHELON-1 trial and treatment strategies in Hodgkin’s lymphoma.

1. What are the limitations of current ABVD chemotherapy regimes for advanced Hodgkin’s lymphoma? (0:10)

2. Could you tell us a little about the ECHELON-1 study and its findings? (1:04)

3. What toxicities were associated with the A+AVD regimen? (2:11)

4. What patients are most likely to respond to this approach? (4:46)

5. What future studies are planned? (6:05)

Speaker disclosures: Martin Hutchings has nothing to disclose in relation to this video interview.

Filmed at the 23rd Annual Congress of the European Association of Hematology (EHA), Stockholm, Sweden, June 14–17 2018

A+AVD = brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine; ABVD = doxorubicin, bleomycin, vinblastine, and dacarbazine

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup